New hope for thyroid eye disease: phase 3 drug trial shows promise

NCT ID NCT06625411

Ongoing Disease control Sponsor: Viridian Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 33 times

Summary

This study tests an investigational drug called VRDN-003 in 132 people with active thyroid eye disease, a condition that causes eye bulging, redness, and discomfort. The goal is to see if the drug can reduce eye bulging by at least 2 millimeters compared to a placebo. Participants receive either the drug or a placebo injection, and researchers monitor safety and effectiveness over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

A.P.J. Office

Newport Beach, California, 92660, United States
Advancing Research International, LLC

Los Angeles, California, 90023, United States
Agile Clinical Research Trials, LLC

Atlanta, Georgia, 30328, United States
Alliance Research Institute - Canoga Park

Canoga Park, California, 91304, United States
Alliance Research Institute - Lynwood

Lynwood, California, 90262, United States
Anmed Health Services LLC

Miami, Florida, 33193, United States
Asheville Clinical Research

Asheville, North Carolina, 28803, United States
Baylor College of Medicine/Alkek Eye Center

Houston, Texas, 77030, United States
Byers Eye Institute at Stanford University

Palo Alto, California, 94303, United States
C&A Clinical Trials Corp

Cape Coral, Florida, 33990, United States
Continental Clinical Research

Miami, Florida, 33144, United States
Duke Eye Center

Durham, North Carolina, 27705, United States
Fraser Eye Care Center

Fraser, Michigan, 48026, United States
Gulf Coast Clinical Trials

Houston, Texas, 77070, United States
Hype Clinical Research LLC

Miami, Florida, 33145, United States
Ilumina Medical Research

Kissimmee, Florida, 34744, United States
Kahana Oculoplastic & Orbital Surgery

Livonia, Michigan, 48152, United States
Marvel Clinical Research

Huntington Beach, California, 92647, United States
Med-Care Research

Miami, Florida, 33125, United States
Neuro-Eye Clinical Trials

Houston, Texas, 77074, United States
Opthalmic Consultants of Boston

East Weymouth, Massachusetts, 02189, United States
Pasadena Clinical Trials

Pasadena, California, 91101, United States
Roski Eye Institute, Keck School of Medicine, USC

Los Angeles, California, 90033, United States
Rutgers New Jersey Medical School

Newark, New Jersey, 07103, United States
S.L. Office

Las Vegas, Nevada, 89144, United States
Sarasota Retina Institute

Sarasota, Florida, 34239, United States
Scottsdale Clinical Trials

Scottsdale, Arizona, 85260, United States
Senta Clinic

San Diego, California, 92108, United States
United Medical Research Institute

Inglewood, California, 90301, United States
University Health

Kansas City, Missouri, 64108, United States
University of Washington, Eye institute

Seattle, Washington, 98104, United States
Vector Clinical Trials

Sparks, Nevada, 89436, United States
Vision Medical Research

Orland Park, Illinois, 60462, United States
West Virginia University Eye Institute

Morgantown, West Virginia, 26506, United States

Conditions

Explore the condition pages connected to this study.

THYROID EYE DISEASE